brought to you by CORE

Festuccia *et al. Journal of Hematology & Oncology* (2018) 11:38 https://doi.org/10.1186/s13045-018-0587-3

Journal of Hematology & Oncology

CORRECTION





Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

C. Festuccia^{1*}, A. Mancini², A. Colapietro², G. L. Gravina^{2,3}, F. Vitale⁴, F. Marampon³, S. Delle Monache⁵, S. Pompili⁶, L. Cristiano⁷, A. Vetuschi⁶, V. Tombolini⁸, Y. Chen⁹ and T. Mehrling¹⁰

Erratum

The original article [1] contained an error whereby Fig. 4 displayed incorrect magnification scales. This has now been corrected, and can be seen ahead

and in the original article [1].

Author details

¹Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ²Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ³Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ⁴Division of Neurosciences, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ⁵Division of Applied Biology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, Italy. ⁶Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ⁶Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ⁷Laboratory of Applied Biology, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. ⁸Division of Radiotherapy, Department of Experimental Medicine, University of Rome "La Sapienza", Rome, Italy. ⁹Northlake International LLC, Pleasanton, CA, USA. ¹⁰Mundipharma-EDO GmbH, Basel, Switzerland.

Received: 8 March 2018 Accepted: 8 March 2018 Published online: 14 March 2018

Reference


 Festuccia C, et al. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol. 2018;11:32.

* Correspondence: claudio.festuccia@univaq.it

¹Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which pernits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.



cells after treatments with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μ M. b Morphological changes observed in U87MG cells after treatments with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μ M. c Representative expression of acidic vacuolar organelle (AVO) accumulation in T98G cells cultured with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μ M. d Percentage of AVO-stained cells in U87MG, U251, and T98G cells cultured with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μ M. Statistical analysis: *p < 0.005 in the comparison between combined TINO + RT treatment and RT alone. Single results are representative of three different experiments performed in triplicate. e Immunocytochemical evaluation of γ H2Ax stain in T98G cells treated with 4, 6, and 8 Gy (RT) alone or in association with TINO 3.5 μ M. f Quantization of γ H2AX expression in U87MG, U251, and T98G cells treated with RT with or without TINO. Statistical analyses: *p < 0.005 in the comparison between RT + TINO and RT or TINO treatments alone. Single results are representative of three different experiments performed in triplicate